The New England journal of medicine, 2020-11, Vol.383 (22), p.2127-2137
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
- Ist Teil von
- The New England journal of medicine, 2020-11, Vol.383 (22), p.2127-2137
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The causal role of neutrophil serine proteases in the pathogenesis of bronchiectasis was studied with brensocatib, an inhibitor of protease activation. Brensocatib therapy resulted in a longer time to the first bronchiectasis exacerbation than placebo.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2021713Titel-ID: cdi_proquest_journals_2464400730
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Benzoxazoles - administration & dosage, Benzoxazoles - adverse effects, Bronchiectasis, Bronchiectasis - drug therapy, Bronchiectasis - metabolism, Cell activation, Clinical trials, Cystic fibrosis, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - antagonists & inhibitors, Disease Progression, Dose-Response Relationship, Drug, Double-Blind Method, Elastase, Female, Forced Expiratory Volume, Humans, Leukocyte Elastase - metabolism, Leukocytes (neutrophilic), Male, Middle Aged, Neutrophils, Oxazepines - administration & dosage, Oxazepines - adverse effects, Patients, Peptidase, Pharmacodynamics, Quality of life, Questionnaires, Serine, Serine Proteases - metabolism, Serine proteinase, Sputum, Sputum - metabolism